LOGIN  |  REGISTER
Cue Biopharma
Recursion

The Oncology Institute Executives to Participate in Multiple Panel Presentations at APG 2024 Spring Conference

May 22, 2024 | Last Trade: US$0.31 0.005 -1.59

CERRITOS, Calif., May 22, 2024 (GLOBE NEWSWIRE) -- Today, the Oncology Institute, Inc. and its affiliates (NASDAQ: TOI) have announced their executives’ participation in multiple panel presentations at the upcoming APG 2024 Spring Conference in San Diego. Chief Medical Officer, Dr. Yale Podnos, will be discussing artificial intelligence and its uses in an oncology practice in the breakout session panel “AI on the Front Lines: Improving Outcomes and Reducing Costs for Complex Patients”. Dr. Daniel Virnich, Chief Executive Officer, will join other industry leaders on another panel, “Assuming Global Risk for Pharmaceuticals.”

About The Oncology Institute

Founded in 2007, The Oncology Institute, Inc. and its affiliates (NASDAQ: TOI) is advancing oncology by delivering highly specialized, value-based cancer care in the community setting. TOI offers cutting-edge, evidence-based cancer care to a population of more than 1.8 million patients including clinical trials, transfusions, and other care delivery models traditionally associated with the most advanced care delivery organizations. With 110+ employed clinicians and over 70 clinic locations and growing, TOI is changing oncology for the better. For more information visit www.theoncologyinstitute.com.

Contacts

Investors at Solebury Strategic Communications

This email address is being protected from spambots. You need JavaScript enabled to view it.

Stock Quote

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB